Inyx to Present at Rodman & Renshaw Healthcare Conference NEW YORK, May 2 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, will be presenting at the Rodman & Renshaw Techvest Annual Global Healthcare Conference in Paris, France. Inyx's presentation will be this Thursday, May 5, at 4:35 p.m. Paris time, which is 10:35 a.m. Eastern Daylight Time in the United States. A webcast of the Inyx presentation will be available both live and on a recorded basis for 90 days afterwards at: http://www.wsw.com/webcast/rrshq5/iyxi.ob. The webcast link can also be accessed from the Investor Relations/Investor Presentation section at Inyx's website: http://www.inyxinc.com/. The presentation will feature an overview of Inyx's business niches and corporate goals, including Inyx's just completed acquisition of the assets and certain business of Aventis Pharmaceuticals Puerto Rico from Aventis Pharmaceuticals, Inc., a wholly owned subsidiary of sanofi-aventis Group (NYSE:SNY). Inyx will also discuss other new business and strategic relationships the Company is gaining as well as Inyx's own initial proprietary products that are expected to be ready for commercial marketing by the end of 2005. About Inyx Inyx, Inc. is a specialty pharmaceutical company with aerosol drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services to the international healthcare market. In addition, Inyx is developing its own proprietary products to be marketed by selected clients and strategic partners, which include some of the largest pharmaceutical companies. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA, Ltd., which has newly acquired operations in Manati, Puerto Rico; Inyx Pharma Limited, which has development and production facilities located near Manchester, England; and Inyx Canada, Inc. based in Toronto, which provides business development and support services. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit: http://www.inyxinc.com/. Safe Harbor Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. For more information, please contact: Jay M. Green, Executive VP Inyx, Inc. DATASOURCE: Inyx, Inc. CONTACT: Jay M. Green, Executive VP of Inyx, Inc., Web site: http://www.inyxinc.com/

Copyright